Efficacy of intracervicovaginal misoprostol in second-trimester pregnancy termination: a comparison between live and dead fetuses
- PMID: 9564098
- DOI: 10.1111/j.1447-0756.1998.tb00044.x
Efficacy of intracervicovaginal misoprostol in second-trimester pregnancy termination: a comparison between live and dead fetuses
Abstract
Objective: To study the complications and compare the success rate and abortion time between the live and the dead fetuses in second-trimester pregnancy termination with intracervicovaginal misoprostol.
Design: A prospective comparative study.
Subjects and methods: A total of 89 pregnant women between 14 and 28 weeks of gestation with obstetric, medical, or genetic reasons for termination of pregnancy were recruited to receive 200 micrograms misoprostol inserted intracervicovaginally every 12 hours.
Results: The rates of successful abortions within 12, 24 and 48 hours in live fetuses were 15.1%, 54.7% and 92.5%, respectively, while in dead fetuses were 50.0%, 83.3% and 97.2%, respectively. The success rates within 12 and 24 hours in live-fetus group were significantly lower than those of the dead-fetus group 9p = 0.0009 and p = 0.01, respectively). The mean abortion time of the live-fetus group (27.1 hours) was significantly more than that of the dead-fetus group (15 hours, p = 0.001). No serious complications occurred in terms of hemorrhage, febrile morbidity diarrhea, nausea and vomiting.
Conclusions: Intracervicovaginal misoprostol is an effective and safe method for second-trimester pregnancy termination. The success rate is higher and the abortion time is less in dead-fetus pregnancy than those in the live-fetus pregnancy.
Similar articles
-
Termination of second-trimester pregnancy with intracervicovaginal misoprostol.J Med Assoc Thai. 1997 Apr;80(4):242-6. J Med Assoc Thai. 1997. PMID: 9175393
-
Termination of second trimester, complicated gestation.East Mediterr Health J. 2005 Jul;11(4):657-62. East Mediterr Health J. 2005. PMID: 16700381
-
Randomized controlled trial of misoprostol for second-trimester pregnancy termination associated with fetal malformation.Am J Obstet Gynecol. 2004 Mar;190(3):755-62. doi: 10.1016/j.ajog.2003.09.037. Am J Obstet Gynecol. 2004. PMID: 15042010 Clinical Trial.
-
Interruption of nonviable pregnancies of 24-28 weeks' gestation using medical methods: release date June 2013 SFP guideline #20133.Contraception. 2013 Sep;88(3):341-9. doi: 10.1016/j.contraception.2013.05.001. Epub 2013 May 9. Contraception. 2013. PMID: 23756114 Review.
-
Forensic Toxicological Aspects of Misoprostol Use in Pharmacological Abortions.Molecules. 2022 Oct 3;27(19):6534. doi: 10.3390/molecules27196534. Molecules. 2022. PMID: 36235071 Free PMC article. Review.
Cited by
-
Outcomes of Pregnancy Termination of Dead Fetus in Utero in Second Trimester by Misoprostol with Various Regimens.Int J Environ Res Public Health. 2022 Oct 3;19(19):12655. doi: 10.3390/ijerph191912655. Int J Environ Res Public Health. 2022. PMID: 36231955 Free PMC article.
-
Risk Factors for Failure of Second-Trimester Termination with Misoprostol as a Single Agent.J Clin Med. 2024 Sep 9;13(17):5332. doi: 10.3390/jcm13175332. J Clin Med. 2024. PMID: 39274544 Free PMC article.
-
Effectiveness and adverse effects of vaginal misoprostol as a single agent for second trimester pregnancy termination: the impact of fetal viability.Arch Gynecol Obstet. 2024 Apr;309(4):1459-1466. doi: 10.1007/s00404-023-07068-8. Epub 2023 May 6. Arch Gynecol Obstet. 2024. PMID: 37149516
-
Does feticide shorten termination duration in second trimester pregnancy terminations?Afr Health Sci. 2019 Mar;19(1):1544-1553. doi: 10.4314/ahs.v19i1.28. Afr Health Sci. 2019. PMID: 31148982 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical